Tempus AI (TEM) Evp, CLO Polovin Andrew Sells $221K of Stock
Key Points
- Tempus AI, Inc. EVP and Chief Legal Officer Andrew Polovin sold 2,951 shares at $75.00 each for a total of $221,325 on September 17, 2026, under a pre-arranged plan.
- The company reported trailing-twelve-month revenue of $1.43 billion and an EPS of -$1.44, with its next earnings report slated for November 2, 2026.
- Major institutions like ARK Investment Management and Baillie Gifford adjusted their holdings in recent reporting periods.
Since the trade, $TEM is up 2.3% after 1 week and down 19.5% to date (from the $80.36 close on Sep 17, 2026).
Get Tempus AI text alerts
We text you when insiders, Congress, analysts or big funds move on $TEM.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Tempus AI, Inc. alert may contain errors. Disclosures
Tempus AI, Inc. EVP and Chief Legal Officer Andrew Polovin sold 2,951 shares of the company on September 17, 2026. According to a Form 4 filed with the SEC, the transaction was executed at a price of $75.00 per share, amounting to a total value of $221,325.
TEM
Tempus AI, Inc.
Inside Andrew Polovin's Tempus AI Trade
The sale by Polovin involved 2,951 shares valued at $75.00 apiece, bringing in $221,325 for the executive. This transaction was carried out under a pre-arranged Rule 10b5-1 plan. On the day of the trade, Tempus AI stock closed at $80.36.
Other Institutional Activity in Tempus AI
ARK Investment Management, LLC grew its holdings by 415,048 shares, ending with 10,022,634 shares worth about $648,664,884. BAILLIE GIFFORD & CO reduced its holdings by 459,284 shares, ending with 8,190,133 shares worth about $530,065,417. Softbank Group Corporation kept its stake unchanged, holding 5,405,406 shares valued at roughly $349,837,882. Sumitomo Mitsui Trust Group, Inc. cut its position by 237,070 shares, finishing with 4,089,029 shares worth about $264,641,961. Amova Asset Management Americas Inc also trimmed its stake by 237,070 shares, leaving it with 4,089,029 shares valued at roughly $264,641,961.
Tempus AI, Inc. Stock Down 6.6%
Recent trading put the shares around $63.83 as of October 16, 2026, which is down about 20.6% from the closing price on the day of Polovin's trade.
Recent Earnings
Tempus AI posted trailing-twelve-month revenue of $1.43 billion alongside a negative earnings per share of $1.44. The healthcare technology firm carries a net profit margin of -17.8% and a return on equity of -67.4%. Investors look ahead to the next earnings release scheduled for November 2, 2026.
Insider Buying and Selling at Tempus AI, Inc.
Prior to this trade, several insiders completed transactions, including director Nadja Y. West selling 3,000 shares on August 28, 2026, for $207,000. Director David R Epstein sold 250 shares on September 1, 2026, for $16,388, while director Jennifer A. Ph.D. Doudna sold 676 shares that same day for $44,312. Officer Ryan Fukushima also sold 30,846 shares on September 1, 2026, valued at $1,934,244.
Analysts Set New Price Targets
Rothschild & Co initiated coverage on September 8, 2026, with a Neutral rating and a $67.00 price target. Roth Capital also initiated coverage on September 8, 2026, with a Neutral rating and a $67.00 target. UBS followed on September 9, 2026, with a Neutral rating and a $70.00 target, while HC Wainwright & Co. maintained a Buy rating and raised its target to $66.00 on September 11, 2026. Later, Goldman Sachs initiated coverage with a Neutral rating and a $75.00 target on September 21, 2026. Overall, the stock carries a consensus Buy recommendation with 18 analyst opinions and a mean price target of $74.94.
About Tempus AI
Tempus AI, Inc. operates a healthcare technology platform in the United States that bridges clinical care and advanced diagnostics. The company provides software and laboratory tools that help physicians integrate molecular data and next-generation sequencing tests into routine patient treatment. Executive transactions like this happen routinely as part of personal portfolio management.
Bottom Line
Investors will be tracking the upcoming earnings report on November 2, 2026, for updates on revenue growth and profitability. Monitoring further Form 4 filings will show whether other executives continue executing sales under planned schedules.
Related Filing Alerts
Source: Polovin Andrew's Form 4 filing on $TEM (Sep 17, 2026). Written by software, not financial advice. How we make alerts